Logo image of CRDL

CARDIOL THERAPEUTICS INC-A (CRDL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRDL - CA14161Y2006 - Common Stock

1 USD
-0.05 (-4.76%)
Last: 12/8/2025, 8:01:34 PM
1.05 USD
+0.05 (+5%)
Pre-Market: 12/9/2025, 4:01:22 AM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRDL. CRDL was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CRDL have multiple concerns. CRDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDL has reported negative net income.
In the past year CRDL has reported a negative cash flow from operations.
CRDL had negative earnings in each of the past 5 years.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL Yearly Net Income VS EBIT VS OCF VS FCFCRDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -268.65%, CRDL is not doing good in the industry: 91.62% of the companies in the same industry are doing better.
The Return On Equity of CRDL (-363.82%) is worse than 76.96% of its industry peers.
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL Yearly ROA, ROE, ROICCRDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CRDL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL Yearly Profit, Operating, Gross MarginsCRDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CRDL has been increased compared to 1 year ago.
CRDL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CRDL has a worse debt to assets ratio.
CRDL Yearly Shares OutstandingCRDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL Yearly Total Debt VS Total AssetsCRDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -6.30, we must say that CRDL is in the distress zone and has some risk of bankruptcy.
CRDL has a worse Altman-Z score (-6.30) than 65.44% of its industry peers.
CRDL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CRDL has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -6.3
ROIC/WACCN/A
WACCN/A
CRDL Yearly LT Debt VS Equity VS FCFCRDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 3.89. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.89, CRDL perfoms like the industry average, outperforming 58.64% of the companies in the same industry.
CRDL has a Quick Ratio of 3.89. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRDL (3.89) is better than 60.21% of its industry peers.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.89
CRDL Yearly Current Assets VS Current LiabilitesCRDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.07% over the past year.
EPS 1Y (TTM)24.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38%
EPS Next 2Y-5.51%
EPS Next 3Y19.04%
EPS Next 5Y26.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL Yearly Revenue VS EstimatesCRDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CRDL Yearly EPS VS EstimatesCRDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL Price Earnings VS Forward Price EarningsCRDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL Per share dataCRDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

CRDL's earnings are expected to grow with 19.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.51%
EPS Next 3Y19.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

NASDAQ:CRDL (12/8/2025, 8:01:34 PM)

Premarket: 1.05 +0.05 (+5%)

1

-0.05 (-4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners11.32%
Inst Owner Change12.66%
Ins Owners4.3%
Ins Owner ChangeN/A
Market Cap99.49M
Revenue(TTM)N/A
Net Income(TTM)-34.78M
Analysts82.5
Price Target7.19 (619%)
Short Float %1.99%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-30.72%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)12.55%
Min EPS beat(4)-30.72%
Max EPS beat(4)32.64%
EPS beat(8)5
Avg EPS beat(8)3.01%
EPS beat(12)9
Avg EPS beat(12)9.06%
EPS beat(16)13
Avg EPS beat(16)12.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.53%
PT rev (3m)-11.63%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)15.07%
EPS NY rev (3m)15.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.37
P/tB 14.37
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.89
Altman-Z -6.3
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y38%
EPS Next 2Y-5.51%
EPS Next 3Y19.04%
EPS Next 5Y26.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y13.88%
EBIT Next 5Y25.41%
FCF growth 1Y12.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.36%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIOL THERAPEUTICS INC-A / CRDL FAQ

What is the ChartMill fundamental rating of CARDIOL THERAPEUTICS INC-A (CRDL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRDL.


What is the valuation status for CRDL stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIOL THERAPEUTICS INC-A (CRDL). This can be considered as Overvalued.


Can you provide the profitability details for CARDIOL THERAPEUTICS INC-A?

CARDIOL THERAPEUTICS INC-A (CRDL) has a profitability rating of 0 / 10.


How financially healthy is CARDIOL THERAPEUTICS INC-A?

The financial health rating of CARDIOL THERAPEUTICS INC-A (CRDL) is 3 / 10.


What is the earnings growth outlook for CARDIOL THERAPEUTICS INC-A?

The Earnings per Share (EPS) of CARDIOL THERAPEUTICS INC-A (CRDL) is expected to grow by 38% in the next year.